Loading…
Reported covered position: Health Professional Staff, Senate Health, Education, Labor, and Pensions Committee; Legislative Assistant, Sen. Mark Kirk
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128, the VALID Act of 2021), and use of diagnostic tests to improve public health
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS via ANDREW VOGT STRATEGIES LLC
2022 · third_quarter · 3T
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), telehealth, and use of diagnostic tests to improve public health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2022 · fourth_quarter · 4T
Source: Senate LDA
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), telehealth, and use of diagnostic tests to improve public health
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), telehealth, and use of diagnostic tests to improve public health
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
VALID Act of 2021
Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS · Firm: ANDREW VOGT STRATEGIES LLC
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
TRANSPLANT Act of 2021
Client: ALLIANCE FOR CELL THERAPY NOW · Firm: ANDREW VOGT STRATEGIES LLC
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies
TRANSPLANT Act of 2021
Client: ALLIANCE FOR CELL THERAPY NOW · Firm: ANDREW VOGT STRATEGIES LLC
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health and Department of Health and Human Services; implementation of the 21st Century Cures Act; regulation of regenerative medicine and cell therapies.
Increased funding for research on regenerative medicine and cell therapies at the National Institutes of Health and Department of Health and Human Services; Implementation of the 21st Century Cures Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2022 · third_quarter · Q3
Increased funding for research on regenerative medicine and cell therapies at the National Institutes of Health and Department of Health and Human Services; Implementation of the 21st Century Cures Act
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health and Department of Health and Human Services; implementation of the 21st Century Cures Act; regulation of regenerative medicine and cell therapies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS via ANDREW VOGT STRATEGIES LLC
2022 · second_quarter · Q2
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2022 · second_quarter · Q2
Increased funding for research on regenerative medicine and cell therapies at the National Institutes of Health and Department of Health and Human Services; Implementation of the 21st Century Cures Act
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health and Department of Health and Human Services; implementation of the 21st Century Cures Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS via ANDREW VOGT STRATEGIES LLC
2022 · first_quarter · 1A
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2022 · first_quarter · Q1
Increased funding for research on regenerative medicine and cell therapies at the National Institutes of Health; Implementation of the 21st Century Cures Act
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health; implementation of the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS via ANDREW VOGT STRATEGIES LLC
2022 · first_quarter · RR
Regulation of diagnostic tests (including H.R. 4128, the VALID Act of 2021), and use of diagnostic tests to improve public health
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2021 · fourth_quarter · Q4
Increased funding for research on regenerative medicine and cell therapies at the National Institutes of Health; Implementation of the 21st Century Cures Act
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health; implementation of the 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2021 · third_quarter · Q3
Increased funding for research on regenerative medicine and cell-based therapies at the National Institutes of Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2021 · second_quarter · Q2
Funding for regenerative medicine and cell-based therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR CELL THERAPY NOW via ANDREW VOGT STRATEGIES LLC
2021 · second_quarter · RR
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies